Know Cancer

forgot password

A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer

Phase 1/Phase 2
18 Years
Open (Enrolling)
Hormone Refractory Prostate Cancer

Thank you

Trial Information

A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer

Detailed description not necessary.

Inclusion Criteria:

Each subject must meet the following criteria to be enrolled in this study.

1. Patients must have histologically or cytologically confirmed adenocarcinoma of the
prostate that is clinically refractory to hormone therapy.

2. Zubrod Performance Status 0-1.

3. At the time of enrollment, patients must have evidence of progressive metastatic
disease, either:

- Measurable disease with any level of serum PSA

- OR

- Non-measurable disease with PSA ≥ 5 ng/ml. Patients with PSA ≥ 5 ng/ml only and
no other radiographic evidence of metastatic prostate cancer are not eligible.

4. Patients must have demonstrated evidence of progressive disease since the most recent
change in therapy. Progressive disease is defined as any one of the following
(measurable disease, bone scan, or PSA progression):

- Measurable Disease Progression

- Bone Scan Progression

- PSA Progression

5. Serum testosterone ≤ 50 ng/ml, determined within two weeks prior to starting

6. Maintaining castrate status: Patients who have not undergone surgical orchiectomy
should continue on medical therapies [e.g. gonadotropin releasing hormone analogs
(GnRH analogs)] to maintain castrate levels of serum testosterone.

7. Megestrol acetate (MEGACE®) treatment may continue if patient has been on stable
doses of the drug.

8. Age > 18 years of age.

9. Four weeks since major surgery.

10. The following restrictions on prior therapy for metastatic disease apply:

- No prior chemotherapy regimen for metastatic disease.

- No more than one prior course of palliative radiotherapy.

- Up to one prior treatment with a non-chemotherapeutic agent (e.g., kinase
inhibitors, immunotherapeutic agents, etc) is permitted as treatment for
metastatic disease.

- No prior radioisotope therapy with Strontium-89, Samarium or similar agents.

- One prior neo-adjuvant or adjuvant chemotherapy regimen is permitted if given
over 3 years ago.

11. No limitation on prior hormonal therapy.

12. Patients should be off all therapy for at least 4 weeks prior to study drug

13. Life expectancy should be ≥ 3 months.

14. Patients must have signed an informed consent document stating that they understand
the investigational nature of the proposed treatment.

15. Required Initial Laboratory Data:

- WBC ≥ 3,000/µl

- ANC ≥ 1,500/µl

- Platelet count ≥ 100,000/µl

- Creatinine ≤ 1.5 x

- Total Bilirubin ≤ (exceptions will be made for patients with Gilbert's Disease)

- SGOT (AST) ≤ 1.5 x

- SGPT (ALT) ≤ 1.5 x

16. Men whose sexual partners are of child-bearing age must agree to use adequate
contraception (hormonal or barrier method of birth control) for the duration of study

17. If obese (weight > 20% of ideal body weight) patient must be treated with doses
calculated using adjusted BSA.

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from the study.

1. Patients may not be receiving any other investigational agents.

2. Patients may continue on a daily Multi-Vitamin, low dose (≤ 400 IU qd) Vitamin D,
Calcitrol (≤ 0.5 mcg qd), and calcium supplements, but all other herbal, alternative
and food supplements (i.e. PC-Spes, Saw Palmetto, St John Wort, etc.) must be
discontinued before registration.

3. Patients on stable doses of bisphosphonates, who develop subsequent tumor
progression, may continue on this medication.However, patients may not initiate
bisphosphonate therapy prior to or during study

4. Patients with known brain metastases.

5. Patients with history of allergic reactions attributed to solvent-based docetaxel

6. Patients with significant cardiovascular disease including congestive heart failure,
active angina pectoris or recent myocardial infarction (within the last 6 months).

7. Patients with a "currently active" second malignancy other than non-melanoma skin

8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

9. HIV-positive patients receiving combination anti-retroviral therapy.

Type of Study:


Study Design:

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

DLT's and MTD's

Outcome Time Frame:

1 Year

Safety Issue:


Principal Investigator

John C Araujo, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

April 2007

Completion Date:

May 2012

Related Keywords:

  • Hormone Refractory Prostate Cancer
  • Prostatic Neoplasms



University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan  48109-0752
Washington University School of Medicine Saint Louis, Missouri  63110
Nebraska Methodist Hospital Omaha, Nebraska  68114
University of Texas M.D. Anderson Cancer Center Houston, Texas  77030